Resmetirom for liver health after transplant in MASH patients
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a liver transplant at least 12 months ago for MASH cirrhosis and now have new fat in your liver, or you had a transplant for another reason and developed fatty liver after.
- You have at least one metabolic risk factor, like overweight, diabetes, high blood pressure, high triglycerides, or low good cholesterol.
- You have moderate to advanced liver scarring confirmed by noninvasive tests and a liver biopsy.
- Your kidney function is stable and good enough (eGFR at least 30).
- Your liver enzyme levels are stable and not getting worse.
- You have been on the same immunosuppressive medications for at least 3 months.
- You are not using too much alcohol (checked by a blood test) and have no other active liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
This study tests a daily pill, resmetirom, to see if it can reduce fat and scarring in the livers of children and teens with MASH, a type of fatty liver disease. It may help improve liver health and prevent further damage.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This trial tests a new drug called TGM-312-SC01 to see if it can help people with MASH (a type of fatty liver disease that causes inflammation and damage). It is for adults aged 18 to 70 who are otherwise healthy or have MASH.
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
This study tests whether adding a special nutrition plan to the medication resmetirom helps people with MASH (a type of fatty liver disease) and moderate liver scarring. It's for New York City residents who are starting resmetirom anyway.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.